- Home
- MFIN vs NVCT Comparison
MFIN vs NVCT Comparison
Compare MFIN & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFIN
- NVCT
- Stock Information
- Founded
- MFIN 1995
- NVCT 2020
- Country
- MFIN United States
- NVCT United States
- Employees
- MFIN N/A
- NVCT N/A
- Industry
- MFIN Finance: Consumer Services
- NVCT Medicinal Chemicals and Botanical Products
- Sector
- MFIN Finance
- NVCT Health Care
- Exchange
- MFIN Nasdaq
- NVCT Nasdaq
- Market Cap
- MFIN 223.8M
- NVCT 184.9M
- IPO Year
- MFIN 1996
- NVCT 2022
- Fundamental
- Price
- MFIN $9.62
- NVCT $7.78
- Analyst Decision
- MFIN
- NVCT Strong Buy
- Analyst Count
- MFIN 0
- NVCT 3
- Target Price
- MFIN N/A
- NVCT $17.00
- AVG Volume (30 Days)
- MFIN 63.5K
- NVCT 265.7K
- Earning Date
- MFIN 07-30-2025
- NVCT 08-05-2025
- Dividend Yield
- MFIN 4.94%
- NVCT N/A
- EPS Growth
- MFIN N/A
- NVCT N/A
- EPS
- MFIN 1.60
- NVCT N/A
- Revenue
- MFIN $316,751,000.00
- NVCT N/A
- Revenue This Year
- MFIN N/A
- NVCT N/A
- Revenue Next Year
- MFIN $5.67
- NVCT N/A
- P/E Ratio
- MFIN $6.06
- NVCT N/A
- Revenue Growth
- MFIN 13.91
- NVCT N/A
- 52 Week Low
- MFIN $7.21
- NVCT $4.44
- 52 Week High
- MFIN $10.50
- NVCT $11.80
- Technical
- Relative Strength Index (RSI)
- MFIN 54.11
- NVCT 44.12
- Support Level
- MFIN $9.38
- NVCT $7.70
- Resistance Level
- MFIN $9.70
- NVCT $8.24
- Average True Range (ATR)
- MFIN 0.24
- NVCT 0.44
- MACD
- MFIN -0.00
- NVCT 0.03
- Stochastic Oscillator
- MFIN 55.93
- NVCT 27.52
About MFIN Medallion Financial Corp.
Medallion Financial Corp is a finance company that originates and services loans in various industries. The five operating segments are, (1) recreation, (2) home improvement, (3) commercial, (4) taxi medallion, and (5) strategic partnership loans. The company generates maximum revenue from the Recreation segment.
About NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.